Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | TSHR | P16473 | 7/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SCN1A | P35498 | 4/20 | 0.50 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455175 | 0.90 | TSHR (0.62) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL18669066 | 0.88 | TSHR (0.63) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL9279757 | 0.87 | ALDH1A1 (0.79) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL6061788 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL6440654 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL6062258 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| Acetic Acid SCHEMBL29214004 | 0.85 | TSHR (0.57) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL27359798 | 0.85 | TSHR (0.57) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL36533 | 0.85 | ALDH1A1 (0.67) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 | |
| SCHEMBL4257844 | 0.84 | ALDH1A1 (0.58) | ALDH1A1TSHRTDP1L3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8169090-B2 | Encapsulating resin composition for preapplication, semiconductor device made with the same, and process for producing the same | SUMITOMO BAKELITE COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090166897-A1 | ENCAPSULATING RESIN COMPOSITION FOR PREAPPLICATION, SEMICONDUCTOR DEVICE MADE WITH THE SAME, AND PROCESS FOR PRODUCING THE SAME | SUMITOMO BAKELITE CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | ALDH1A1 867/4885TSHR 3638/4885TDP1 3497/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | ALDH1A1 875/4885TSHR 3680/4885TDP1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.